Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 9Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × efatutazone × Clear all
NCT00986440 2020-11-05

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

Daiichi Sankyo

Phase 2 Terminated
84 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Daiichi Sankyo

Phase 1/2 Terminated
19 enrolled 13 charts
EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated
9 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡